Second malignancies following treatment for Hodgkin's disease: a Greek experience
Economopoulos, T.; Stathakis, N.; Alexopoulos, C.; Pavlidis, N.; Constantinidou, M.; Briassoulis, E.; Papageorgiou, E.; Dervenoulas, J.; Pappa, V.; Vaslamatzis, M.
Haematologica 79(3): 273-276
1994
ISSN/ISBN: 0390-6078 PMID: 7926979 Document Number: 431150
The risk and the type of second malignancies (SM) developing in 217 treated Hodgkin's disease (HD) patients were studied. The median age of the patients was 35 years (range 14-83) and the M/F ratio 1.8. Treatment consisted of radiotherapy alone (24 patients, 11%), chemotherapy alone (96 patients, 44.3%), or a combination of both modalities (43 patients, 19.8%), while 54 patients (24.9%) received salvage treatment. The median follow-up time was 67 months (range 12-224). Ten patients developed a SM with a 5-year and 10-year actuarial risk of 3.3% and 5.4%, respectively. There were 3 cases of ANLL, and MDS (actuarial risk of 2.4% at 6 years), 1 case of nonHodgkin's lymphoma and 6 cases of solid tumors (actuarial risk of 3.2% at 10 years). The risk of developing SM was higher in males and older patients ( gt 40 years). SM represent a serious late side effect of successful treatment for HD. The possibility of developing a SM must be taken into consideration in the initial treatment of the disease.